Loading
Breast Cancer Treatment Studies / Advanced Radiotherapy Techniques · Journal article
Radiation Oncology Journal · September 4, 2026
Encouraging direction, but not yet definitive.
This single-institution retrospective study of 89 early-stage breast cancer patients treated with single-dose 20 Gy IOeRT-PBI reports 98.8% 5-year OS, 82.9% PFS, and 1.1% ipsilateral breast tumor recurrence with no grade ≥3 toxicity. Although results are encouraging in a carefully selected low-risk cohort, the short median follow-up (33 months), lack of prospective design, and absence of a comparison arm limit the strength of evidence; the authors acknowledge that longer follow-up and prospective validation are needed.
Retrospective cohort study, single institution. Patients with early-stage breast cancer treated with IOeRT-PBI; predominantly T1 tumors (84.3%), most without G3 grading or HER2 overexpression. Single institution; detailed eligibility criteria not stated.. Intervention: Single-dose 20 Gy intraoperative electron radiotherapy (IOeRT) for partial breast irradiation (PBI). n = 89. Single institution; geographic location not specified..
60-month OS 98.8% and PFS 82.9% after median follow-up of 33 months with single-dose 20 Gy IOeRT-PBI Ipsilateral breast tumor recurrence 1.1% (one of 89 patients) after 56 months; six patients with disease progression, five due to distant metastases No grade ≥3 toxicity; acute adverse events included radiogenic dermatitis (15.7%) and seroma formation (8.9%); fatigue most common late adverse event (5.6%)
No grade ≥3 toxicity; acute adverse events included radiogenic dermatitis (15.7%) and seroma formation (8.9%); fatigue most common late adverse event (5.6%)
These results suggest IOeRT-PBI is a viable option for selected early-stage breast cancer patients with favourable toxicity and early local control. However, clinicians should await prospective validation and longer follow-up before adopting this as standard practice, particularly given the small number of progression events in higher-risk subgroups (T2 or node-positive disease).
A single-institution retrospective analysis of 89 low-risk patients shows encouraging local control (98.8% OS, 1.1% ipsilateral recurrence) and low toxicity with IOeRT-PBI, but requires longer follow-up and prospective validation to establish practice-changing evidence.
As stated by the source record.
Quoted from the source exactly as published.
These results suggest IOeRT-PBI is a viable option for selected early-stage breast cancer patients with favourable toxicity and early local control. However, clinicians should await prospective validation and longer follow-up before adopting this as standard practice, particularly given the small number of progression events in higher-risk subgroups (T2 or node-positive disease).
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Purpose: Partial breast irradiation (PBI) using intraoperative electron radiotherapy (IOeRT) represents an attractive alternative to whole-breast irradiation in carefully selected patients with early breast cancer. Materials and Methods: Eighty-nine patients treated with single-dose 20Gy IOeRT between December 2012 and October 2022 were retrospectively analyzed.Most patients had early-stage disease, predominantly T1 tumors (84.3%), without adverse pathological features such as G3 grading or human epidermal growth factor receptor 2 overexpression.Follow-up examinations were conducted postoperatively, at 6 weeks, and every 6 months thereafter.Outcomes included overall survival (OS), progression-free survival (PFS), and in-breast progression-free survival, assessed using Kaplan-Meier analysis.The impact of clinical and treatment-related factors (e.g., age, tumor stage, grading, receptor status, endocrine therapy, electron energy, tumor localization, and re-resection) on survival and adverse events (AEs) was evaluated using log-rank tests and bivariate analyses.Results: After a median follow-up of 33 months, OS and PFS at 60 months were 98.8% and 82.9%, respectively.Six patients developed disease progression; only one experienced local recurrence after 56 months (ipsilateral breast tumor recurrence 1.1%), while the remaining cases were distant metastases.No ≥grade 3 toxicity occurred.Acute AEs included radiogenic dermatitis (15.7%) and seroma formation (8.9%), whereas fatigue was the most common late AE (5.6%).No significant associations between evaluated factors and survival outcomes or AEs were observed.Notably, two progression events occurred in patients with T2 or node-positive disease.Conclusion: IOeRT-PBI demonstrated encouraging short-term local control and low toxicity in this real-world low-risk cohort.While results are consistent with existing intraoperative radiotherapy data, longer follow-up and prospective validation are warranted before broader clinical implementation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.